From the Journals

Putting a number on biologic DMARD costs

Publish date: January 17, 2018
By
Richard Franki

 

FROM ARTHRITIS CARE & RESEARCH

Annual medical costs for patients with rheumatoid arthritis were almost three times higher for those who used biologic disease-modifying antirheumatic drugs (bDMARDs), compared with those who used any treatment regimen, according to meta-analysis of 12 studies conducted since bDMARDs were introduced in 1999.

RA patients who used bDMARDs had an average direct cost of $36,053 per year, which was 2.9 times higher than the $12,509 in annual direct medical costs for all RA patients on any treatment regimen. Proportionately, the difference was even greater for RA-specific care, with the annual cost of bDMARD care ($20,262) 5.4 times higher than that of all treatment regimens ($3,723), reported Andrew Hresko and his associates at Brigham and Women’s Hospital, Boston.

Annual medical costs for patients with rheumatoid arthrtitis
“Costs associated with RA are in line with those for other prominent chronic diseases,” such as diabetes ($14,732 a year), multiple sclerosis ($23,195 a year), and ulcerative colitis ($4,032 to $13,722), they wrote. “Our findings also suggest that the burden of RA patients on the U.S. health care system may become outsized compared to the disease’s relatively small prevalence and compared to patients with these other chronic conditions as more patients use bDMARDs in the future.”

Funding for the study was supported through a grant from the National Institutes of Health. Mr. Hresko was supported by a fellowship from Tufts University. One of his associates receives research support from grants to his hospital from Amgen, Pfizer, Eli Lilly, AstraZeneca, Genentech, Bristol Myers Squibb, and Corrona. The third investigator is now an employee of Amgen but was not during the study.

SOURCE: Hresko A et al. Arthritis Care Res. 2018 Jan 5. doi: 10.1002/acr.23512.

Recommended Reading

For women with RA, small-joint surgery rate nearly twice that of men
MDedge Family Medicine
Biosimilars and sources show mostly parallel safety profiles
MDedge Family Medicine
Arthritis prevalence higher than previously thought, especially in adults under 65
MDedge Family Medicine
Health disparities in rural America: Chronic conditions
MDedge Family Medicine
Early weight change has no special effect on mortality in RA
MDedge Family Medicine
Testing for latent tuberculosis infection
MDedge Family Medicine
FDA approves infliximab biosimilar Ixifi for all of Remicade’s indications
MDedge Family Medicine
Children of moms with RA have higher risk of RA, too
MDedge Family Medicine
Chikungunya virus goes undetected despite chronic arthritis in 25% of patients after 20 months
MDedge Family Medicine
Novel herpes zoster vaccine is more cost effective than old vaccine
MDedge Family Medicine

Related Articles